drugset / Trial / NCT06827717
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Phase 2
Recruiting
29 enrolled
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The current study is an investigator-initiated, single-arm phase 2 study that enrolled patients with recurrent and/or metastatic Ewing sarcoma for the treatment of Irinotecan Liposome (II) Combined with Temozolomide and Fluzoparib as the second-line treatment.
Timeline
- Start
- 2025-04-15
- Primary completion
- 2027-04
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 50 mg | — |
| Subject | Temozolomide | Small molecule | 30 mg/m2 | — |
| Subject | irinotecan liposome (II) | Unknown | 56.5 mg/m2 | Intravenous |